Syrian Arab Republic

Syrian Arab Republic

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
3.08 (2.99 - 3.17) 2019 Modelled IHME
3.21 (3.12 - 3.29) 2018 Modelled IHME
3.26 (3.17 - 3.35) 2017 Modelled IHME
3.24 (3.15 - 3.33) 2016 Modelled IHME
3.22 (3.12 - 3.32) 2015 Modelled IHME
3.23 (3.14 - 3.32) 2014 Modelled IHME
3.26 (3.17 - 3.35) 2013 Modelled IHME
3.31 (3.22 - 3.40) 2012 Modelled IHME
3.37 (3.27 - 3.45) 2011 Modelled IHME
3.43 (3.33 - 3.52) 2010 Modelled IHME
3.51 (3.41 - 3.61) 2009 Modelled IHME
3.64 (3.53 - 3.74) 2008 Modelled IHME
3.78 (3.66 - 3.89) 2007 Modelled IHME
3.94 (3.80 - 4.06) 2006 Modelled IHME
4.08 (3.92 - 4.23) 2005 Modelled IHME
4.22 (4.06 - 4.37) 2004 Modelled IHME
4.35 (4.18 - 4.51) 2003 Modelled IHME
4.49 (4.30 - 4.66) 2002 Modelled IHME
4.63 (4.44 - 4.82) 2001 Modelled IHME
4.79 (4.57 - 4.99) 2000 Modelled IHME
4.96 (4.73 - 5.16) 1999 Modelled IHME
5.14 (4.89 - 5.36) 1998 Modelled IHME
5.33 (5.06 - 5.56) 1997 Modelled IHME
5.52 (5.23 - 5.77) 1996 Modelled IHME
5.72 (5.38 - 6) 1995 Modelled IHME
5.92 (5.56 - 6.21) 1994 Modelled IHME
6.12 (5.73 - 6.42) 1993 Modelled IHME
6.32 (5.89 - 6.67) 1992 Modelled IHME
6.53 (6.02 - 6.92) 1991 Modelled IHME
6.74 (6.18 - 7.20) 1990 Modelled IHME
1.12 (0.80 - 1.54) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.82 (0.67 - 0.96) 2019 Modelled IHME
1.2 (1.01 - 1.39) 2018 Modelled IHME
1.43 (1.19 - 1.69) 2017 Modelled IHME
1.53 (1.27 - 1.82) 2016 Modelled IHME
1.57 (1.28 - 1.89) 2015 Modelled IHME
1.49 (1.22 - 1.79) 2014 Modelled IHME
1.29 (1.06 - 1.55) 2013 Modelled IHME
1.05 (0.86 - 1.26) 2012 Modelled IHME
0.85 (0.69 - 1.03) 2011 Modelled IHME
0.77 (0.62 - 0.93) 2010 Modelled IHME
0.77 (0.63 - 0.93) 2009 Modelled IHME
0.79 (0.65 - 0.94) 2008 Modelled IHME
0.82 (0.67 - 0.97) 2007 Modelled IHME
0.85 (0.70 - 1.01) 2006 Modelled IHME
0.89 (0.72 - 1.06) 2005 Modelled IHME
0.93 (0.75 - 1.10) 2004 Modelled IHME
0.98 (0.78 - 1.15) 2003 Modelled IHME
1.04 (0.82 - 1.22) 2002 Modelled IHME
1.1 (0.86 - 1.31) 2001 Modelled IHME
1.18 (0.91 - 1.42) 2000 Modelled IHME
1.27 (0.99 - 1.50) 1999 Modelled IHME
1.37 (1.09 - 1.61) 1998 Modelled IHME
1.49 (1.20 - 1.75) 1997 Modelled IHME
1.65 (1.34 - 1.94) 1996 Modelled IHME
1.84 (1.49 - 2.19) 1995 Modelled IHME
2.13 (1.75 - 2.51) 1994 Modelled IHME
2.57 (2.12 - 3.04) 1993 Modelled IHME
3.13 (2.58 - 3.71) 1992 Modelled IHME
3.78 (3.11 - 4.51) 1991 Modelled IHME
4.49 (3.64 - 5.43) 1990 Modelled IHME
0.37 (0.24 - 0.57) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
36 (28 - 45) 2019 Modelled IHME
36 (28 - 46) 2018 Modelled IHME
36 (28 - 46) 2017 Modelled IHME
36 (28 - 46) 2016 Modelled IHME
36 (28 - 46) 2015 Modelled IHME
36 (28 - 46) 2014 Modelled IHME
36 (28 - 45) 2013 Modelled IHME
36 (29 - 46) 2012 Modelled IHME
37 (29 - 46) 2011 Modelled IHME
37 (29 - 46) 2010 Modelled IHME
37 (29 - 46) 2009 Modelled IHME
37 (29 - 46) 2008 Modelled IHME
37 (30 - 46) 2007 Modelled IHME
38 (30 - 47) 2006 Modelled IHME
38 (30 - 47) 2005 Modelled IHME
38 (30 - 48) 2004 Modelled IHME
38 (31 - 48) 2003 Modelled IHME
39 (31 - 48) 2002 Modelled IHME
39 (31 - 49) 2001 Modelled IHME
39 (31 - 49) 2000 Modelled IHME
39 (31 - 49) 1999 Modelled IHME
39 (31 - 49) 1998 Modelled IHME
39 (31 - 50) 1997 Modelled IHME
39 (31 - 49) 1996 Modelled IHME
39 (31 - 50) 1995 Modelled IHME
39 (31 - 50) 1994 Modelled IHME
39 (31 - 50) 1993 Modelled IHME
39 (31 - 50) 1992 Modelled IHME
39 (31 - 50) 1991 Modelled IHME
39 (31 - 49) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
47 2018 Survey/reported WHO/UNICEF
48 2017 Survey/reported WHO/UNICEF
42 2016 Survey/reported WHO/UNICEF
41 2015 Survey/reported WHO/UNICEF
47 2014 Survey/reported WHO/UNICEF
71 2013 Survey/reported WHO/UNICEF
43 2012 Survey/reported WHO/UNICEF
66 2011 Survey/reported WHO/UNICEF
84 2010 Survey/reported WHO/UNICEF
84 2009 Survey/reported WHO/UNICEF
83 2008 Survey/reported WHO/UNICEF
83 2007 Survey/reported WHO/UNICEF
83 2006 Survey/reported WHO/UNICEF
83 2005 Survey/reported WHO/UNICEF
82 2004 Survey/reported WHO/UNICEF
81 2003 Survey/reported WHO/UNICEF
80 2002 Survey/reported WHO/UNICEF
80 2001 Survey/reported WHO/UNICEF
79 2000 Survey/reported WHO/UNICEF
78 1999 Survey/reported WHO/UNICEF
77 1998 Survey/reported WHO/UNICEF
76 1997 Survey/reported WHO/UNICEF
75 1996 Survey/reported WHO/UNICEF
74 1995 Survey/reported WHO/UNICEF
64 1994 Survey/reported WHO/UNICEF
23 1993 Survey/reported WHO/UNICEF
5 1992 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
0 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016
HBV elimination goal
HBV National Action Plan
HepB birth dose policy
Yes
Eligible for HBV generic medicines
Year of birth dose introduction
2003
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
2.87 (2.34 - 3.55) 2019 Modelled IHME
2.85 (2.33 - 3.53) 2018 Modelled IHME
2.82 (2.30 - 3.51) 2017 Modelled IHME
2.75 (2.25 - 3.39) 2016 Modelled IHME
2.66 (2.15 - 3.30) 2015 Modelled IHME
2.59 (2.10 - 3.21) 2014 Modelled IHME
2.53 (2.06 - 3.14) 2013 Modelled IHME
2.48 (2 - 3.08) 2012 Modelled IHME
2.42 (1.94 - 3.02) 2011 Modelled IHME
2.36 (1.89 - 2.95) 2010 Modelled IHME
2.29 (1.85 - 2.84) 2009 Modelled IHME
2.22 (1.80 - 2.76) 2008 Modelled IHME
2.15 (1.74 - 2.66) 2007 Modelled IHME
2.08 (1.68 - 2.59) 2006 Modelled IHME
2.01 (1.62 - 2.50) 2005 Modelled IHME
1.93 (1.56 - 2.39) 2004 Modelled IHME
1.84 (1.50 - 2.26) 2003 Modelled IHME
1.76 (1.44 - 2.15) 2002 Modelled IHME
1.69 (1.39 - 2.05) 2001 Modelled IHME
1.67 (1.36 - 2.04) 2000 Modelled IHME
1.67 (1.37 - 2.04) 1999 Modelled IHME
1.68 (1.38 - 2.05) 1998 Modelled IHME
1.7 (1.39 - 2.06) 1997 Modelled IHME
1.72 (1.40 - 2.10) 1996 Modelled IHME
1.74 (1.41 - 2.13) 1995 Modelled IHME
1.79 (1.46 - 2.19) 1994 Modelled IHME
1.91 (1.55 - 2.34) 1993 Modelled IHME
2.06 (1.68 - 2.54) 1992 Modelled IHME
2.24 (1.82 - 2.77) 1991 Modelled IHME
2.44 (1.98 - 3.06) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

People who inject drugs (PWID)
Download
Value (%) Year Type Source
3.3 (1.80 - 5.60) 2014 Survey/reported UNDP, 2014

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
36 (27 - 45) 2019 Modelled IHME
36 (26 - 45) 2018 Modelled IHME
35 (26 - 44) 2017 Modelled IHME
35 (26 - 44) 2016 Modelled IHME
35 (26 - 44) 2015 Modelled IHME
35 (26 - 44) 2014 Modelled IHME
35 (26 - 44) 2013 Modelled IHME
35 (26 - 44) 2012 Modelled IHME
34 (26 - 43) 2011 Modelled IHME
34 (25 - 43) 2010 Modelled IHME
34 (25 - 42) 2009 Modelled IHME
34 (25 - 42) 2008 Modelled IHME
34 (25 - 42) 2007 Modelled IHME
34 (25 - 42) 2006 Modelled IHME
34 (25 - 42) 2005 Modelled IHME
33 (25 - 42) 2004 Modelled IHME
33 (24 - 41) 2003 Modelled IHME
33 (24 - 41) 2002 Modelled IHME
33 (24 - 41) 2001 Modelled IHME
32 (24 - 41) 2000 Modelled IHME
32 (24 - 41) 1999 Modelled IHME
33 (24 - 41) 1998 Modelled IHME
33 (24 - 41) 1997 Modelled IHME
33 (24 - 41) 1996 Modelled IHME
33 (25 - 41) 1995 Modelled IHME
33 (25 - 41) 1994 Modelled IHME
33 (24 - 41) 1993 Modelled IHME
33 (24 - 42) 1992 Modelled IHME
34 (24 - 42) 1991 Modelled IHME
34 (25 - 42) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016
HBV elimination goal
HBV National Action Plan
HepB birth dose policy
Yes
Eligible for HBV generic medicines
Year of birth dose introduction
2003
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
3.08 (%)
2019
(2.99 - 3.17(%))
IHME
HCV (RNA/cAg+)
2.87 (%)
2019
(2.34 - 3.55(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
553
2019
(375 - 800)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
1,041
2019
(729 - 1,413)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.82 (%)
2019, latest modelled
(0.67 - 0.96(%))
IHME

Prevalence PWID

HCV
3.30 (%)
2014, survey/surveillance
(1.80 - 5.60(%))
UNDP, 2014

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

HCV
0
2016
(0 - 0)
Harm Reduction International, 2016
Eligible for HBV generic medicines
Eligible for HCV generic medicines